Funding Opportunity RFA-FD-18-017 from the NIH Guide for Grants and Contracts. The purpose of this project is to identify skin physiology characteristics that differ between healthy and skin disease population groups and incorporate them into dermal physiologically-based pharmacokinetic models to improve their predictability. The models developed will be utilized to perform virtual bioequivalence assessments between brand name and generic drug products to inform regulatory decisions relating to the development of generic topical dermatological drug products and transdermal delivery systems.

Notice NOT-AG-18-005 from the NIH Guide for Grants and Contracts

Notice NOT-EB-18-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-FD-18-010 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to support the research necessary to elucidate how systematic alterations to the qualitative (Q1) and/or quantitative (Q2) composition of topical formulations impacts their physical, structural, and functional properties. A key aspect of the research relates to understanding how the thermodynamic properties of a topical dosage form change as it undergoes metamorphosis during dose application and drying on the skin, how the drug's thermodynamic activity profile during the metamorphosis of the dosage form may compare between compositionally different (non-Q1 and/or non-Q2) topical formulations, and how these and other forces may modulate the rate and extent to which topically applied drugs may become available at or near their site(s) of action in the skin. Another key aspect of the research relates to identifying and understanding other potential failure modes for bioequivalence (BE) and/or therapeutic equivalence (TE) (e.g., differences in irritation potential) that may arise between compositionally different (non-Q1 and/or non-Q2) topical formulations.

Notice NOT-CA-18-057 from the NIH Guide for Grants and Contracts

Notice NOT-RM-18-016 from the NIH Guide for Grants and Contracts

Notice NOT-NR-18-005 from the NIH Guide for Grants and Contracts

Notice NOT-DK-18-011 from the NIH Guide for Grants and Contracts

Notice NOT-NR-18-006 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-025 from the NIH Guide for Grants and Contracts

Notice NOT-NR-18-003 from the NIH Guide for Grants and Contracts

Notice NOT-HL-18-605 from the NIH Guide for Grants and Contracts

Notice NOT-EB-18-007 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-032 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-033 from the NIH Guide for Grants and Contracts

Notice NOT-NR-18-004 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-016 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-055 from the NIH Guide for Grants and Contracts

Notice NOT-HL-18-606 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-18-005 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to solicit applications for the Sexually Transmitted Infections Cooperative Research Centers (STI CRC) program. This STI CRC program will facilitate multidisciplinary, synergistic collaborations to support the development of vaccines to control and prevent sexually transmitted infections (STIs) caused by the following pathogens, which have limited candidates in the product development pipeline: Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum. In addition, the FOA will support the development of prophylactic vaccines for herpes simplex virus (HSV).